Promising results for Optina treatment of diabetic macular edema

Ampio Pharmaceuticals have announced positive results for the OptimEyes trial, which tested a new treatment for diabetic macular edema.
The aim of the study was to test the effectiveness of Optina, an orally administered drug designed to treat diabetic macular edema.
Diabetic macular edema is a fairly common diabetic complication, affecting around 30 per cent of people with diabetes over the age of 20. It is characterised by a loss of central vision – which usually manifests as blurriness – and is caused by a build-up of fluid in the macula.
Optina treats diabetic macular edema by strengthening the connections between cells, thereby preventing the leakage of fluid across the cell membrane.
The researchers found that orally administered Optina was perfectly safe. None of the participants experienced any serious side effects from the drug.
Moreover, a significant number of the participants experienced significant improvements in their vision and retinal swelling.
The trial is at an early stage, but, should it prove successful, it could lead to promising new developments in the treatment of diabetic macular edema.
Once the trial is complete, and thorough analysis conducted, Ampio Pharmaceuticals plans to submit the data to the US Food and Drug Administration (FDA).